Cargando…
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy
Despite the high efficacy and safety of arsenic trioxide (ATO) in treating acute promyelocytic leukemia (APL) and eradicating APL leukemia-initiating cells (LICs), the mechanism underlying its selective cytotoxicity remains elusive. We have recently demonstrated that APL cells undergo a novel cell d...
Autores principales: | Li, Tao, Ma, Ruishuang, Zhang, Yan, Mo, Hongdan, Yang, Xiaoyan, Hu, Shaoshan, Wang, Lixiu, Novakovic, Valerie A, Chen, He, Kou, Junjie, Bi, Yayan, Yu, Bo, Fang, Shaohong, Wang, Jinghua, Zhou, Jin, Shi, Jialan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833714/ https://www.ncbi.nlm.nih.gov/pubmed/29362482 http://dx.doi.org/10.1038/s41419-017-0018-3 |
Ejemplares similares
-
A Review of Arsenic Trioxide and Acute Promyelocytic Leukemia
por: Alimoghaddam, Kamran
Publicado: (2014) -
On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia
por: Zhang, Peng
Publicado: (2017) -
Treatment of Acute Promyelocytic Leukemia with Single-Agent Arsenic Trioxide
por: Mathews, Vikram, et al.
Publicado: (2011) -
Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment
por: Chen, Baowei, et al.
Publicado: (2013) -
Arsenic trioxide induces macrophage autophagy and atheroprotection by regulating ROS-dependent TFEB nuclear translocation and AKT/mTOR pathway
por: Fang, Shaohong, et al.
Publicado: (2021)